Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 5/20 | 0.37 |
| ▸ | ULK1 | O75385 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | IKBKB | O14920 | 2/20 | 0.34 |
| ▸ | CHUK | O15111 | 2/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL90897 | 0.86 | ABL1 (0.36) | SMOPDK2PDK4NPY5RABL1 | |
| SCHEMBL90921 | 0.85 | SMO (0.37) | SMOPDK2PDK4NPY5RIKBKB | |
| SCHEMBL8572135 | 0.85 | NPY5R (0.36) | SMOPDK2PDK4NPY5RABL1 | |
| SCHEMBL90850 | 0.82 | PDK2 (0.43) | SMOAXLPDK2PDK4NPY5R | |
| SCHEMBL90860 | 0.81 | CCR6 (0.37) | SMOAXLPDK2PDK4NPY5R | |
| SCHEMBL8596030 | 0.80 | PDK2 (0.39) | SMOPDK2PDK4NPY5RIKBKB | |
| SCHEMBL90911 | 0.79 | SMO (0.36) | SMOPDK2PDK4NPY5R | |
| SCHEMBL8554483 | 0.79 | PDK2 (0.37) | SMOAXLPDK2PDK4NPY5R | |
| SCHEMBL90861 | 0.78 | NPY5R (0.49) | SMOULK1NPY5RIKBKBCHUK | |
| SCHEMBL90942 | 0.77 | PDK2 (0.38) | SMOPDK2PDK4NPY5RIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8299066-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-8129372-B2 | Compounds having NPY Y5 receptor antagonistic activity | SHIONOGI & CO., LTD. (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | Shinonogi & Co., Ltd (JP) | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130070-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | SMO 1772/4885ULK1 4354/4885AXL 474/4885 |
| US-20110028468-A1 | COMPOUNDS HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY | NPY5R, NPY1R, NPY2R | SMO 1772/4885ULK1 4354/4885AXL 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.